Myriad Shares Fall Following Court Decision | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Shares of Myriad Genetics fell around 5 percent in Tuesday trade following yesterday's ruling by a federal District Court that declared Myriad's BRCA gene patents invalid.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: diatom genetic diversity, microfluidic droplet method for single-cell screening, and more.

Scientific publishers are looking into whether artificial intelligence can help the peer-review process, Wired reports.

Researchers are using gene editing to develop more robust livestock and crops, AFP reports.

Researchers rally near the American Association for the Advancement of Science annual meeting in Boston.